Mezigdomide, Carfilzomib, and Dexamethasone vs. Carfilzomib and Dexamethasone in relapsed/refractory MM

A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM):SUCCESSOR-2 (CA057008)

Disease Types: Myelomas

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM):SUCCESSOR-2 (CA057008)

For More Information:

https://clinicaltrials.gov/study/NCT05552976?term=SUCCESSOR-2&rank=1